- 专利标题： T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA
-
申请号： US16665708申请日： 2019-10-28
-
公开(公告)号： US11168150B2公开(公告)日： 2021-11-09
- 发明人: Nai-Kong V. Cheung , Mahiuddin Ahmed , Andres Lopez-Albaitero , Cheng Liu , Su Yan , Jingyi Xiang , Hong Liu
- 申请人： Memorial Sloan Kettering Cancer Center , Eureka Therapeutics, Inc.
- 申请人地址： US NY New York; US CA Emeryville
- 专利权人： Memorial Sloan Kettering Cancer Center,Eureka Therapeutics, Inc.
- 当前专利权人： Memorial Sloan Kettering Cancer Center,Eureka Therapeutics, Inc.
- 当前专利权人地址： US NY New York; US CA Emeryville
- 代理机构： Choate, Hall & Stewart LLP
- 代理商 Brenda Herschbach Jarrell; Tracy L. Vrablik
- 主分类号： C07K16/08
- IPC分类号： C07K16/08 ; C07K16/46 ; C07K16/28 ; G01N33/68 ; A61K39/00
摘要：
Described herein are antibodies, fragments thereof and multi-specific binding agents that bind an Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) peptide presented by HLA class I molecules, in particular, HLA-A02. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by expression of an EBV-LMP2 peptide presented by HLA-A02, in particular, Burkit's lymphoma, Hodgkin's lymphoma and nasopharyngeal carcinoma.
信息查询
